The financials from Google Finance say a little bit more. Negative net income since 2008. Retained earnings that have grown increasingly negative since 2008. Share price under a buck even though it's only been public since December 2011. Oh, BTW, the company used to be known as Oncolin Therapeutics. I have no idea what they used to do under that name but it doesn't look like they're doing much anyway now.
That's enough for this one. Really.
Full disclosure: No position in BERX at all, ever.